Medivir AB
MVR0
Company Profile
Business description
Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.
Contact
Lunastigen 5
PO Box 1086, 2nd floor
Huddinge141 22
SWET: +46 854683100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
10
Stocks News & Analysis
stocks
Ask the analyst: Are IDP Education's woes temporary?
The global education services provider has gone from stock market darling to one of the ASX's weakest performers. What gives?
stocks
Is it time to buy the Magnificent Seven?
After the recent selloff, the bull market’s most in-demand stocks look much cheaper.
stocks
Chart of the week: Did ASX companies underwhelm or impress during earnings season?
The Chart of the Week looks at how our Fair Values changes for Australian companies during earnings season.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,966.60 | 136.80 | -1.69% |
| CAC 40 | 7,938.21 | 50.75 | -0.64% |
| DAX 40 | 22,567.14 | 109.27 | -0.48% |
| Dow JONES (US) | 40,724.45 | 626.48 | -1.52% |
| FTSE 100 | 8,542.56 | 46.57 | 0.55% |
| HKSE | 23,462.65 | 319.49 | -1.34% |
| NASDAQ | 17,255.43 | 393.02 | -2.23% |
| Nikkei 225 | 36,790.03 | 3.08 | -0.01% |
| NZX 50 Index | 12,209.05 | 201.92 | -1.63% |
| S&P 500 | 5,509.98 | 89.32 | -1.60% |
| S&P/ASX 200 | 7,749.10 | 141.00 | -1.79% |
| SSE Composite Index | 3,358.73 | 13.20 | -0.39% |